Skip to main content

Featured

20 Turkish Soldiers Killed in Georgia Military Plane Crash

Members of emergency services work at the site of the Turkish C-130 military cargo plane crash near the Azerbaijani border, in Sighnaghi municipality, Georgia. Turkey’s Ministry of Defense announced that 20 soldiers were killed when a military transport plane crashed in Georgia . The aircraft, a C-130 cargo plane, had departed from Azerbaijan and was en route to Turkey when communication was lost shortly after takeoff. Georgian emergency teams reported that 18 bodies were recovered at the crash site , with search operations continuing to locate the remaining victims. Witnesses shared footage showing the plane breaking apart mid-air before spiraling down into farmland near the Azerbaijani border. This tragedy is Turkey’s deadliest military aviation accident in recent years . Both Turkish and Georgian authorities have launched investigations, and officials confirmed that the aircraft’s black box has been recovered . President Recep Tayyip Erdoğan expressed condolences to the families...
Post a Comment
Read more

article

Labels

New Hope for Alzheimer’s Patients: Health Canada Approves First Disease-Modifying Treatment


Health Canada has granted conditional approval for LEQEMBI® (lecanemab), a groundbreaking therapy shown to slow the progression of early Alzheimer’s disease. Developed by Eisai Co., Ltd. and Biogen Inc., the drug is the first in Canada to directly target one of the underlying causes of the disease by reducing amyloid-beta aggregates in the brain.

LEQEMBI is authorized for adults diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease, specifically for patients who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology.

The approval follows results from the global Clarity AD Phase 3 trial, which demonstrated that lecanemab significantly slowed cognitive and functional decline compared to placebo. This milestone offers new hope to the more than 771,000 Canadians currently living with dementia, a number projected to rise to 1 million by 2030.

While the approval comes with conditions requiring further data, experts say this marks a pivotal step in shifting Alzheimer’s treatment from symptom management to disease modification.


Labels:

Comments

Post a Comment